Show simple item record

dc.contributor.authorWahl, Sissel Gyrid Freim
dc.contributor.authorHong, Yan Dai
dc.contributor.authorEmdal, Elisabeth Fritzke
dc.contributor.authorOttestad, Anine Larsen
dc.contributor.authorDale, Vibeke Grotnes
dc.contributor.authorRichardsen, Elin
dc.contributor.authorHalvorsen, Tarje Onsøien
dc.contributor.authorGrønberg, Bjørn Henning
dc.description.abstractDroplet digital polymerase chain reaction (ddPCR) is a highly sensitive and accurate method for quantication of nucleic acid sequences. We used absolute quantication of mutated v-Ki-ras2 Kirsten rat sarcoma viral oncogene homology gene (KRAS) by ddPCR to investigate the prognostic role of mutated KRAS in patients with KRAS-mutated lung adenocarcinomas. Pre-treatment plasma samples from 60 patients with stages I–IV KRAS-mutated lung adenocarcinomas were analysed for KRAS mutations. The associations between survival, detectable KRAS mutations in plasma, and the plasma concentration of mutated KRAS were assessed. Overall, 23 of 60 (38%)patients had detectable KRAS mutation in plasma. The percentage of patients with detectable mutation was 8%in stage I, 30% in stage II, 71% in stage III, and 73% in stage IV. Estimated overall median progression-free survival (PFS) and overall survival (OS) were 26.2 months [95% condence interval (CI) 12.5–39.9] and50.8 months (95% CI 0–107.3), respectively. Patients with detectable mutations in plasma had signicantlyworse median PFS compared to patients with undetectable mutation (13.1 versus 70.1 months) and shorter median OS (20.7 versus not reached). High circulating tumour DNA (ctDNA) concentrations of mutated KRAS were signicantly associated with shorter PFS [hazard ratio (HR) 1.008, 95% CI 1.004–1.012] and OS(HR 1.007, 95% CI 1.003–1.011). All associations remained statistically signicant in multivariable analyses. Inconclusion, ddPCR is an accurate and easily feasible technique for quantication of KRAS mutations in ctDNA.The presence of detectable KRAS mutation in plasma at baseline was associated with worse PFS and OS. High concentration of mutated KRAS in ctDNA was an independent negative prognostic factor for both PFS and OS.en_US
dc.publisherWiley Online Libraryen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titlePrognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.source.journalThe journal of pathology. Clinical researchen_US
dc.description.localcode© 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal